Letrozol Teva

Letrozole, the active ingredient in Letrozol Teva, is a aromatase inhibitor presented as a oral tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozol Teva is an aromatase inhibitor used in the management of hormone‑dependent breast cancer. - Adjuvant treatment of early‑stage hormone receptor‑positive breast cancer in postmenopausal women: reduces risk of recurrence. - Metastatic hormone receptor‑positive breast cancer in postmenopausal women: slows disease progression. - Neoadjuvant therapy before surgery in postmenopausal women with hormone receptor‑positive breast cancer: may shrink tumor size.

Letrozol Teva may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in limbs or back. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Bone fracture: increased risk of osteoporosis. - Pulmonary embolism: sudden shortness of breath. - Allergic reaction: rash, swelling, anaphylaxis. - Elevated cholesterol: dyslipidaemia. - Cardiac arrhythmia: QT interval prolongation.

Before initiating Letrozol Teva, clinicians should consider several safety measures. - Assess bone health: monitor for osteoporosis and consider calcium/vitamin D supplementation. - Monitor liver function: periodic liver enzyme tests are recommended. - Check lipid profile: watch for increases in cholesterol levels. - Contraindicated in pregnancy: teratogenic risk requires strict avoidance. - Use caution in patients with cardiovascular disease: evaluate risk of thromboembolic events. - Store at below 25°C: keep in the original pack, protect from moisture.

Letrozol Teva can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Estrogen replacement therapy: antagonises letrozole's effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly lower plasma concentrations. - Tamoxifen: opposing mechanisms may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may increase INR, requiring closer coagulation monitoring. - CYP2C19 inhibitors (e.g., fluconazole): can raise letrozole exposure. - SSRIs that affect CYP2D6: may alter metabolism and affect efficacy.